Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy
Keywords: Nilotinib; Imatinib; Chronic lymphocytic leukemia; DNA-PK; c-abl; DNA damage and repair mechanisms; Nonhomologous end-joining repair; Homologous recombinational repair;